Abstracts tagged "prevention"

Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Minerva Nong¹, Medha Barbhaiya², Jonah Levine³, Vivian Bykerk⁴, Rachel Heise⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…
Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Andrew Cope¹, Marianna Jasenecova², Joana Vasconcelos³, Andrew Filer⁴, Karim Raza⁵, Sumera Qureshi², Maria Antonietta D'Agostino⁶, Iain McInnes⁷, John Isaacs⁸, Arthur Pratt⁹, Benjamin A Fisher⁴, Christopher Buckley¹⁰, Paul Emery¹¹, Pauline Ho¹², Maya Buch¹³, Coziana Ciurtin¹⁴, René Toes¹⁵, Thomas Huizinga¹⁵, Dirkjan van Schaardenburg¹⁶, Caroline Caroline¹⁷ and Toby Prevost³, ¹King's College London, London, United Kingdom, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁹Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ¹⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Reade, Amsterdam, Netherlands, ¹⁷King's Clinical Trials Unit, King's College London, London, United Kingdom
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium
COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey
Beth Rutstein¹, Merav Heshin Bekenstein², Maria Schletzbaum³, Nora Singer⁴, Rebecca Sadun⁵, Melanie Kohlheim⁶, Vincent Del Gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock⁹, Monica Ardura⁸, Vidya Sivaraman¹⁰ and For the CARRA Investigators¹¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Metro Health, Cleveland, OH, ⁵Duke University, Durham, NC, ⁶None, Columbus, OH, ⁷CARRA, Washington, DC, ⁸Nationwide Children's Hospital, Columbus, OH, ⁹The Ohio State University, Columbus, OH, ¹⁰Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
Abstract Number: L08 • ACR Convergence 2022
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Christopher Podgorski¹ and Deborah Parks², ¹BJC/Washington University Consortium, St. Louis, MO, ²Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…
Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Benjamin Terrier¹, Laura Richert², Grégory Pugnet³, Olivier Aumaitre⁴, Olivier Moranne⁵, Elisabeth Diot⁶, Alexandre Karras⁷, Fabrice Bonnet⁸, Claire De Moreuil⁹, Eric Hachulla¹⁰, Thomas Le Gallou¹¹, Céline Lebas¹⁰, Francois Maurier¹², Cédric Rafat⁷, Maxime Samson¹³, Jean-Francois Augusto¹⁴, Grégoire Couvrat-Devergne¹⁵, Cécile Janssen¹⁶, Thierry Martin¹⁷, Thomas Quemeneur¹⁸, Pierre-Louis Caron¹⁹, Cécile-Audrey Durel²⁰, Khalil El Karoui⁷, Aurélie Grados²¹, Mathieu Puyade²², Virginie Rieu⁴, Yurdagul Uzunhan²³, Jean-Francois Viallard⁸, Xavier Puéchal⁷, Loic Guillevin⁷, Noémie Huchet⁸, Hendy Abdoul⁷, Carine Bellera⁸, Frédéric Batteux⁷ and Odile Launay⁷, ¹Cochin Hospital, Paris, France, ²EUCLID, Bordeaux, France, ³CHU, Toulouse, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Nimes, France, ⁶CHU, Tours, France, ⁷CHU, Paris, France, ⁸CHU, Bordeaux, France, ⁹CHU, Brest, France, ¹⁰CHU, Lille, France, ¹¹CHU, Rennes, France, ¹²CH, Metz, France, ¹³CHU, Dijon, France, ¹⁴CHU, Angers, France, ¹⁵CH, La Roche sur Yon, France, ¹⁶CH, Annecy, France, ¹⁷CHU, Strasbourg, France, ¹⁸CH, Valenciennes, France, ¹⁹CHU, Grenoble, France, ²⁰CHU, Lyon, France, ²¹CH, Niot, France, ²²CHU, Poitiers, France, ²³CHU, Bobigny, France
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
Abstract Number: 0185 • ACR Convergence 2022
Empowered2work: Development and Delivery of a Multi-faceted Peer-coaching Workshop Focusing on Health Promotion and Ergonomic Issues in the Workplace
Erika Mosor, Romualdo Ramos and Tanja Stamm, Medical University of Vienna, CeMSIIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Outcomes Research, Wien, Austria
Background/Purpose: Work and education significantly impact health and quality of life in people with rheumatic and musculoskeletal diseases (RMDs). However, patients often experience internal and…
Abstract Number: 1194 • ACR Convergence 2022
Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
Jenny Gong¹, Emma Barnboym², megan O'Mara³, Natalie Gurevich³, Maya Mattar⁴, Donald Anthony⁵, Adam Perzynski² and Nora Singer⁶, ¹Case Western School of Medicine, Cleveland, OH, ²The MetroHealth System, Cleveland, OH, ³Cleveland Veteran Affairs Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Patients with autoimmune disease are at increased risk for complications from SARS-CoV-2 infection. We aimed to compare patient perspectives on COVID-19 vaccination among persons…
Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Michael Scepaniak, Cockeysville, MD
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
Abstract Number: 0346 • ACR Convergence 2022
Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
George Gennaoui¹, Sana Kang² and J. Patricia Dhar³, ¹Ascension St. John Hospital, St. Clair Shores, MI, ²Ascension St John Hospital, Chesterfield, MO, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in most patients with systematic lupus erythematous (SLE). It is generally a safe; however, it can cause retinal…
Abstract Number: 1200 • ACR Convergence 2022
Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
Karen Costenbader¹, Nancy R Cook², I-Min Lee², Jill Hahn³, Joseph Walter¹, Vadim Bubes¹, Gregory Kotler¹, Nicole Yang¹, Sonia Friedman¹, Erik K Alexander¹ and JoAnn E Manson², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard TH Chan School of Public Health, Brigham and Women's Hospital, Boston, MA, ³Brigham and Womens' Hospital, Boston, MA
Background/Purpose: Strong biologic rationale supports potential effects of both vitamin D and of marine omega-3 (n3) fatty acids for autoimmune disease prevention. Within the randomized…
Abstract Number: 0477 • ACR Convergence 2022
Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
Hubert De Boysson¹, Anael DUMONT², Samuel DESHAYES², Alexandre Nguyen² and Achille Aouba¹, ¹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²Caen University Hospital, Caen, France
Background/Purpose: We analyzed whether the use of beta-blockers in addition to conventional care in patients with Giant cell arteritis (GCA) and large vessel vasculitis (LVV)…
Abstract Number: 1274 • ACR Convergence 2022
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Nagendra Pokala², Dan Wang³, Joan Reisch³, Reuben Arasaratnam³, Bonnie Bermas¹ and Puneet Bajaj³, ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are at risk for severe pneumococcal infections due to their underlying disease and immunosuppressive therapy. Current Advisory Committee on Immunization Practices guidelines…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 1275 • ACR Convergence 2022
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Sana Kang¹, George Gennaoui² and J. Patricia Dhar³, ¹Ascension St John Hospital, Chesterfield, MO, ²Ascension St. John Hospital, St. Clair Shores, MI, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of…

« Previous Page
1
…
6
7
8
9
10
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].